Our laboratory is developing new pharmaceuticals for the prevention and restoration of bone loss. This includes the bone weakening associated with generalized processes such as osteoporosis as well as that occuring in more specialized circumstances (renal osteodystrophy, skeletal metastases). Focus on the underlying structural biology by physical techniques (e.g., X-ray crystallography) and through the development of computational resources (e.g., an integrated, non-proprietary public access program suite designed specifically to assist with rational drug design) will provide new opportunities for identifying and refining novel lead compounds.